Viral interleukin-10 gene inhibition of inflammation, osteoclastogenesis, and bone resorption in response to titanium particles

Arthritis and Rheumatism

Volumn 46, Issue 5, 2002, Pages 1298-1308

  Carmody, Emily E ^a   Schwarz, Edward M ^a   Puzas, J Edward ^a   Rosier, Randy N ^a   O'Keefe, Regis J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; TITANIUM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DEVELOPMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE THERAPY; JOINT PROSTHESIS; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; SYNOVIOCYTE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; FIBROBLASTS; GENE THERAPY; GENETIC VECTORS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MACROPHAGES; OSTEOCLASTS; OSTEOLYSIS; SKULL; SPLEEN; SYNOVIAL MEMBRANE; TITANIUM; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS;

EID: 0036093132     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10227     Document Type: Article

References (61)

1. The problem is osteolysis
2. Charnley total hip arthroplasty in patients less than fifty years old: A twenty to twenty-five-year follow-up
3. Outcome of Charnley total hip replacement across a single health region in England: The results at five years from a regional hip register
4. Primary total hip arthroplasty with a cementless porous-coated anatomic total hip prosthesis: 10- to 12-year results of prospective and consecutive series
5. Wear debris in total joint replacement
6. The problem in total joint arthroplasty: Aseptic loosening
7. Wear of polyethylene acetabular components in total hip arthroplasty: An analysis of one hundred and twenty-eight components retrieved at autopsy or revision operations
8. Human monocyte/macrophage response to cobalt-chromium corrosion products and titanium particles in patients with total joint replacements
9. Composition and morphology of wear debris in failed uncemented total hip replacement
10. Production of cytokines around loosened cemented acetabular components: Analysis with immunohistochemical techniques and in situ hybridization
11. Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implants: A potential role in osteolysis
12. The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis
13. Expression of osteoclast differentiation factor in rheumatoid arthritis
14. Breakthrough in bone: The molecular mechanism of osteoclast/osteoblast coupling revealed
15. Immunosuppressive and anti-inflammatory properties of interleukin 10
16. Role of IL-10 in inflammation: Studies using cytokine knockout mice
17. IL-10 inhibits cytokine synthesis in monocytes stimulated by titanium particles: Evidence of an anti-inflammatory regulatory pathway
18. Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system
19. Gene expressions of antiinflammatory mediators in THR retrieved interfascial membranes
20. Are differences in interleukin 10 production associated with joint damage?
21. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1
22. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1
23. Rheumatoid arthritis
24. Cytokine networks in rheumatoid arthritis: Implications for therapy
25. Anticytokines
26. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model
27. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer
28. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws
29. A quantitiative small animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis
30. Titanium particles increase TNF-alpha and IL-6 protein and mRNA levels in human peripheral blood monocytes
31. Empirical advantages of adeno associated viral vectors for in vivo gene therapy for arthritis
32. Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver
33. NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes
34. Immunological defects in mice with a targeted disruption in Bcl-3
35. Gene therapy promises, problems and prospects
36. Efficacy of Etanercept for wear debris-induced osteolysis
37. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis
38. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis
39. IL-10 inhibits macrophage activation and proliferation by distinct signalling mechanisms: Evidence for stat3-dependent and -independent pathways
40. The Epstein-Barr virus interleukin-10 (IL-10) homolog is a selective agonist with impaired binding to the IL-10 receptor
41. Design and analysis of an engineered human interleukin-10 monomer
42. A single amino acid determines the immunostimulatory activity of interleukin 10
43. Interleukin-10 and the interleukin-10 receptor
44. Interleukin-10 receptor signaling through the JAK-STAT pathway: Requirement for two distinct receptor-derived signals for anti-inflammatory action
45. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
46. Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: Evidence for an inhibitory loop involving endogenous IL-10
47. Inhibition by interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: Its underlying mechanism in comparison with interleukin-4
48. Regulation of chemokine expression by IL-10 in lung inflammation
49. Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10
50. Macrophage deactivation by interleukin 10
51. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
52. Future of adenoviruses in the gene therapy of arthritis
53. Effect of anti-tumor necrosis factor-α gene therapy on wear debris-induced osteolysis
54. Localized, direct plasmid gene delivery in vivo: Prolonged therapy results in reproducible tissue regeneration
55. The adeno-associated virus vector for orthopaedic gene therapy
56. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung
57. Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse
58. Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice
59. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer
60. Viral IL-10 gene transfer decreases inflammation and cell adhesion molecule expression in a rat model of venous thrombosis
61. A randomized, controlled trial of IL-10 in humans: Inhibition of inflammatory cytokine production and immune responses